Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 60, Issue 35, Pages 19074-19078Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202106674
Keywords
biosensor; Levodopa; Parkinson disease; phamacokinetics; therapeutic drug monitoring
Categories
Funding
- NIH National Institute of Neurological Disorders and Stroke [R21 NS114764-01A1]
Ask authors/readers for more resources
Levodopa is the standard medication for symptomatic therapy of Parkinson's disease, but long-term use may lead to motor and non-motor complications. This study introduces an individualized therapeutic drug monitoring method that tracks the drug concentration in fingertip sweat, demonstrating a personalized dose-response relationship.
Levodopa (L-Dopa) is the gold-standard medication for symptomatic therapy of Parkinson disease (PD). However, L-Dopa long-term use is associated with the development of motor and non-motor complications, primarily due to its fluctuating plasma levels in combination with the disease progression. Herein, we present the first example of individualized therapeutic drug monitoring for subjects upon intake of standard L-Dopa oral pill, centered on dynamic tracking of the drug concentration in naturally secreted fingertip sweat. The touch-based non-invasive detection method relies on instantaneous collection of fingertip sweat on a highly permeable hydrogel that transports the sweat to a biocatalytic tyrosinase-modified electrode, where sweat L-Dopa is measured by reduction of the dopaquinone enzymatic product. Personalized dose-response relationship is demonstrated within a group of human subjects, along with close pharmacokinetic correlation between the finger touch-based fingertip sweat and capillary blood samples.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available